BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 22960736)

  • 1. Safe and effective variability-a criterion for dose individualization.
    Holford NH; Buclin T
    Ther Drug Monit; 2012 Oct; 34(5):565-8. PubMed ID: 22960736
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Validation of a novel approach for dose individualization in pharmacotherapy using gabapentin in a proof of principles study.
    Blau GE; Orcun S; LaĆ­nez JM; Reklaitis GV; Suvannasankha A; Fausel C; Anaissie EJ
    Pharmacotherapy; 2013 Jul; 33(7):727-35. PubMed ID: 23553679
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Individualization of drug therapy: history, present state, and opportunities for the future.
    Lesko LJ; Schmidt S
    Clin Pharmacol Ther; 2012 Oct; 92(4):458-66. PubMed ID: 22948891
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Drug dosage individualization based on a random-effects linear model.
    Diaz FJ; Cogollo MR; Spina E; Santoro V; Rendon DM; de Leon J
    J Biopharm Stat; 2012; 22(3):463-84. PubMed ID: 22416835
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Customizing dosage drugs what contribution in therapeutic drug monitoring?].
    Abdessadek M; Magoul R; Amarti A; El Ouezzani S; Khabbal Y
    Ann Biol Clin (Paris); 2014; 72(1):15-24. PubMed ID: 24492095
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Individualized drug and dose: the clinical pharmacologist's calling or curse?
    Begg EJ
    Clin Exp Pharmacol Physiol; 2005 Nov; 32(11):975-8. PubMed ID: 16405455
    [TBL] [Abstract][Full Text] [Related]  

  • 7. How pharmacogenomics (PG) are changing practice: implications for prescribers, their patients, and the healthcare system (PG series part I).
    Preskorn SH; Hatt CR
    J Psychiatr Pract; 2013 Mar; 19(2):142-9. PubMed ID: 23507814
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Therapeutic drug monitoring--the appropriate use of drug level measurement in the care of the neonate.
    Young TE
    Clin Perinatol; 2012 Mar; 39(1):25-31. PubMed ID: 22341534
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapeutic drug monitoring as a component of personalized medicine: applications in pediatric drug development.
    Momper JD; Wagner JA
    Clin Pharmacol Ther; 2014 Feb; 95(2):138-40. PubMed ID: 24253660
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Quantifying the Effectiveness of Dose Individualization by Simulation for a Drug With Moderate Pharmacokinetic Variability.
    Liefaard L; Chen C
    Ther Drug Monit; 2015 Oct; 37(5):641-8. PubMed ID: 26378372
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Individualization of drug dosage--past, present and future.
    Thomson AH
    Med Monatsschr Pharm; 2003 May; 26(5):150-2. PubMed ID: 12784502
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapeutic drug monitoring: A patient management tool for precision medicine.
    Jang SH; Yan Z; Lazor JA
    Clin Pharmacol Ther; 2016 Feb; 99(2):148-50. PubMed ID: 26565378
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Drug dosing in older patients with chronic kidney disease.
    Perrin E
    Am Fam Physician; 2007 Dec; 76(12):1766. PubMed ID: 18217516
    [No Abstract]   [Full Text] [Related]  

  • 14. The mathematics of drug dose individualization should be built with random-effects linear models.
    Diaz FJ; de Leon J
    Ther Drug Monit; 2013 Apr; 35(2):276-7. PubMed ID: 23503456
    [No Abstract]   [Full Text] [Related]  

  • 15. Individualization of drug dosage regimens.
    Platt DR
    Clin Lab Med; 1987 Jun; 7(2):289-99. PubMed ID: 3301171
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Response to Diaz and de Leon "the mathematics of drug dose individualization should be built with random effects linear models".
    Holford NH; Buclin T
    Ther Drug Monit; 2013 Dec; 35(6):873-4. PubMed ID: 24263647
    [No Abstract]   [Full Text] [Related]  

  • 17. Personalised medicines: more tailored drugs, more tailored delivery.
    Florence AT; Lee VH
    Int J Pharm; 2011 Aug; 415(1-2):29-33. PubMed ID: 21565262
    [No Abstract]   [Full Text] [Related]  

  • 18. Medication compliance as a feature in drug development.
    Kastrissios H; Blaschke TF
    Annu Rev Pharmacol Toxicol; 1997; 37():451-75. PubMed ID: 9131261
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Monitoring plasma concentrations to individualize treatment with clomiphene citrate.
    Rostami-Hodjegan A; Lennard MS; Tucker GT; Ledger WL
    Fertil Steril; 2004 May; 81(5):1187-93. PubMed ID: 15136073
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Principles of therapeutic drug monitoring].
    Widmer N; Csajka C; Werner D; Grouzmann E; Decosterd LA; Eap CB; Biollaz J; Buclin T
    Rev Med Suisse; 2008 Jul; 4(165):1644-8. PubMed ID: 18767290
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.